论文部分内容阅读
一项新的研究结果显示,与标准治疗处方相比较,那些含有原生物细菌乳酸杆菌属 reuteri 或双叉杆菌属 lactis 的治疗处方似乎更能减少育儿中心婴儿腹泻的发作频次和持续时间。研究人员在最新出版的《儿科学》杂志上刊文指出,L.reuteri 可作为改善额外死亡率的一种较好的婴儿治疗补充成分。来自于以色列 Soroka 医学中心的 Zvi Weizman博士及其同事分别对201例随机接受 L.reuteri 或B.lactis 或不含原生物细菌治疗处方的婴儿的感染结果的变化情况进行了评估研究。所有受试婴儿身体健康且在 Beer—Sheva 育儿中心受到照料。
A new study showed that treatment regimens containing the indigenous bacterial Lactobacillus reuteri or Bifidobacterium lactis appear to be more effective in reducing the frequency and duration of episodes of infant diarrhea in child-care centers than standard-care prescriptions. In a recent publication in the journal Pediatrics, the researchers pointed out that L.reuteri could be a better infant treatment supplement to improve excess mortality. Dr. Zvi Weizman from the Soroka Medical Center in Israel and colleagues evaluated the changes in the outcome of 201 infants who received either L.reuteri or B.lactis randomly or not treated with indigenous bacteria. All infants tested were healthy and were cared for at the Beer-Sheva Parenting Center.